New Tool for Estimating Alzheimer’s Risk
Introduction to the Predictive Model
A novel tool has been developed to assist scientists in estimating the likelihood of individuals experiencing memory and cognitive issues associated with Alzheimer’s disease. Researchers at the Mayo Clinic have created a predictive model that leverages amyloid PET scans alongside genetic information to assess risk.
Functionality of the Tool
This innovative tool not only predicts the risk of developing mild cognitive impairment (MCI) and dementia but does so even before any symptoms manifest. It provides estimates for both lifetime and 10-year risks, offering valuable insights for early intervention.
Increasing Risk with Age
As individuals age, the probability of cognitive decline increases significantly. By 2025, it is projected that approximately 7 million Americans aged 65 and older will be living with Alzheimer’s disease, a figure that is expected to rise in the coming years.
Research Findings
The Mayo Clinic team emphasized that Alzheimer’s disease begins its progression long before clinical symptoms arise. However, they acknowledged that the relationship between biomarkers and future cognitive risk remained unclear. Utilizing data spanning over two decades, the researchers successfully developed a tool that accurately predicts both the 10-year and lifetime risk of cognitive impairment, taking into account brain scans, age, and genetic factors. These findings have been published in The Lancet Neurology.